Abstract
Human ghrelin and human motilin, belonging to the ghrelin/motilin-related peptide family, share 36% amino acid sequence identity, while the human ghrelin receptor exhibits a remarkable 50% overall identity with the human motilin receptor. In addition to their structural resemblance, ghrelin and motilin are the only two mammalian hormones known to decrease in the postprandial period. Ghrelin and motilin participate in initiating the migrating motor complex in the stomach, and stimulate gastrointestinal motility, accelerate gastric emptying, and induce “gastric hunger”. In addition to modulating the release of growth hormone and gut motility, ghrelin plays a crucial role in the secretion and protection of the stomach and colon. Ghrelin mimetics and motilin agonists are currently being developed to reverse gastrointestinal hypomotility disorders. With additional appetite-enhancing, adiposity-promoting, and anti-inflammatory effects, ghrelin and rikkunshito (a traditional Japanese herb enhancing acyl ghrelin signaling) are superior to motilin in the treatment of cancerrelated anorexia and cachexia, post-chemotherapy symptoms, rheumatological diseases, age-related frailty, as well as post-operative, septic, and post-burn gut ileus.
Keywords: Adiposity, anorexia, appetite, cachexia, gastrointestinal, ghrelin, ileus, inflammation, motilin, motility.
Current Pharmaceutical Design
Title:Ghrelin and Motilin in the Gastrointestinal System
Volume: 18 Issue: 31
Author(s): Chih-Yen Chen and Chang-Youh Tsai
Affiliation:
Keywords: Adiposity, anorexia, appetite, cachexia, gastrointestinal, ghrelin, ileus, inflammation, motilin, motility.
Abstract: Human ghrelin and human motilin, belonging to the ghrelin/motilin-related peptide family, share 36% amino acid sequence identity, while the human ghrelin receptor exhibits a remarkable 50% overall identity with the human motilin receptor. In addition to their structural resemblance, ghrelin and motilin are the only two mammalian hormones known to decrease in the postprandial period. Ghrelin and motilin participate in initiating the migrating motor complex in the stomach, and stimulate gastrointestinal motility, accelerate gastric emptying, and induce “gastric hunger”. In addition to modulating the release of growth hormone and gut motility, ghrelin plays a crucial role in the secretion and protection of the stomach and colon. Ghrelin mimetics and motilin agonists are currently being developed to reverse gastrointestinal hypomotility disorders. With additional appetite-enhancing, adiposity-promoting, and anti-inflammatory effects, ghrelin and rikkunshito (a traditional Japanese herb enhancing acyl ghrelin signaling) are superior to motilin in the treatment of cancerrelated anorexia and cachexia, post-chemotherapy symptoms, rheumatological diseases, age-related frailty, as well as post-operative, septic, and post-burn gut ileus.
Export Options
About this article
Cite this article as:
Chen Chih-Yen and Tsai Chang-Youh, Ghrelin and Motilin in the Gastrointestinal System, Current Pharmaceutical Design 2012; 18 (31) . https://dx.doi.org/10.2174/138161212803216915
DOI https://dx.doi.org/10.2174/138161212803216915 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protective and Therapeutic Effects of Ghrelin in the Gut
Current Medicinal Chemistry Cutaneous Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Non-Viral Gene Delivery Methods
Current Pharmaceutical Biotechnology Evaluating the Risk of Covid-19 Transmission from Conjunctival and Lacrimal Discharge: A Review
Current Biotechnology Microvascular Theory of Exercise-Induced Bronchoconstriction in Asthma: Potential Implication of Vascular Endothelial Growth Factor
Inflammation & Allergy - Drug Targets (Discontinued) Air Pollution Exposure and Blood Pressure: An Updated Review of the Literature
Current Pharmaceutical Design Micro-RNAs, Exercise and Cellular Plasticity in Humans: The Impact of Dietary Factors and Hypoxia
MicroRNA Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Current Drug Targets Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Neurovascular Changes in Acute, sub-Acute and Chronic Mouse Models of Parkinson’s Disease
Current Neurovascular Research L-Arginine in the Prevention and Treatment of Cardiovascular Disease: From Basic to Clinical Research Studies
Vascular Disease Prevention (Discontinued) The Role of Heat Shock Protein 90 and Endothelial Nitric Oxide Synthase Signaling in Cardiovascular Therapy
Current Signal Transduction Therapy Impaired Neurovascular Coupling in the APPxPS1 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Mechanisms, Prevention and Treatment of Distal Embolization
Current Pharmaceutical Design Development and Optimization of Controlled Release Bioerodable Anti Infective Ophthalmic Insert
Current Drug Delivery Oxidative Stress Induced Mitochondrial DNA Deletion as a Hallmark forthe Drug Development in the Context of the Cerebrovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Cardiovascular Morbidity and Mortality in Obstructive Sleep Apnea
Current Pharmaceutical Design Ocular Toxocariasis: New Diagnostic and Therapeutic Perspectives
Recent Patents on Anti-Infective Drug Discovery L-Arginine Analogs – Inactive Markers or Active Agents in Atherogenesis?
Cardiovascular & Hematological Agents in Medicinal Chemistry Platelet Activation in Atherogenesis Associated with Low-Grade Inflammation
Inflammation & Allergy - Drug Targets (Discontinued)